AstraZeneca to develop DNA-based monoclonal Ab platform
27 March 2019 | News
The plasmids will encode monoclonal antibodies developed by AstraZeneca and will be delivered using Ichor’s TriGrid® Delivery System.
image credit- wistar.org
US based Ichor® Medical Systems, Inc. (Ichor) has announced that it has entered into a collaboration and research license agreement with AstraZeneca for the development and clinical assessment of plasmid DNA constructs.
The plasmids will encode monoclonal antibodies developed by AstraZeneca and will be delivered using Ichor’s TriGrid® Delivery System. Under the terms of the agreement, Ichor will receive upfront and annual payments along with development milestones.
The development and optimization of in vivo expression of DNA-encoded antibodies delivered by the TriGrid is a particularly attractive product strategy in the recombinant monoclonal antibody market. Utilizing this approach, the TriGrid platform works to deliver DNA-encoding monoclonal antibodies directly into a person, after which that person’s own cells can begin to manufacture the antibodies.
